ATE393157T1 - Substituierte heterocyclische verbindungen und anwendungsverfahren - Google Patents

Substituierte heterocyclische verbindungen und anwendungsverfahren

Info

Publication number: ATE393157T1
Authority: AT; Austria
Prior art keywords: disease; hiv; syndrome; diabetes; type
Prior art date: 2004-01-22

Application number

AT05711810T

Other languages

English (en)

Inventor

Michael Frohn

Fang-Tsao Hong

Longbin Liu

Patricia Lopez

Aaron Siegmund

Seifu Tadesse

Nuria Tamayo

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-22

Filing date

2005-01-21

Publication date

2008-05-15

2005-01-21 Application filed by Amgen Inc filed Critical Amgen Inc

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE393157T1 publication Critical patent/ATE393157T1/de

Links

238000000034 method Methods 0.000 title abstract 2
150000001420 substituted heterocyclic compounds Chemical class 0.000 title 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 2
241000701022 Cytomegalovirus Species 0.000 abstract 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 2
206010040070 Septic Shock Diseases 0.000 abstract 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 abstract 2
201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 2
208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010063094 Cerebral malaria Diseases 0.000 abstract 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
206010009900 Colitis ulcerative Diseases 0.000 abstract 1
208000011231 Crohn disease Diseases 0.000 abstract 1
206010012442 Dermatitis contact Diseases 0.000 abstract 1
201000005569 Gout Diseases 0.000 abstract 1
206010018634 Gouty Arthritis Diseases 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
206010020164 HIV infection CDC Group III Diseases 0.000 abstract 1
208000007514 Herpes zoster Diseases 0.000 abstract 1
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000034578 Multiple myelomas Diseases 0.000 abstract 1
206010028289 Muscle atrophy Diseases 0.000 abstract 1
208000000112 Myalgia Diseases 0.000 abstract 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
208000010191 Osteitis Deformans Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
208000027868 Paget disease Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
208000033464 Reiter syndrome Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
206010040047 Sepsis Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
230000036783 anaphylactic response Effects 0.000 abstract 1
208000003455 anaphylaxis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
208000019664 bone resorption disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000010247 contact dermatitis Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
206010022000 influenza Diseases 0.000 abstract 1
208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
208000027202 mammary Paget disease Diseases 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 1
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 abstract 1
208000002574 reactive arthritis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000036303 septic shock Effects 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
241000701161 unidentified adenovirus Species 0.000 abstract 1
241001529453 unidentified herpesvirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Biotechnology (AREA)
Obesity (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)

AT05711810T 2004-01-22 2005-01-21 Substituierte heterocyclische verbindungen und anwendungsverfahren ATE393157T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US53894804P	2004-01-22	2004-01-22

Publications (1)

Publication Number	Publication Date
ATE393157T1 true ATE393157T1 (de)	2008-05-15

Family

ID=34807244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05711810T ATE393157T1 (de)	2004-01-22	2005-01-21	Substituierte heterocyclische verbindungen und anwendungsverfahren

Country Status (9)

Country	Link
US (1)	US7504403B2 (de)
EP (1)	EP1716150B1 (de)
JP (1)	JP2007518813A (de)
AT (1)	ATE393157T1 (de)
AU (1)	AU2005206557A1 (de)
CA (1)	CA2553923A1 (de)
DE (1)	DE602005006240T2 (de)
ES (1)	ES2304690T3 (de)
WO (1)	WO2005070932A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102234274B (zh) *	2010-04-28	2012-12-26	中国科学院大连化学物理研究所	一种二环吡啶酮衍生物的合成方法
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
EP3632906B1 (de)	2017-05-24	2023-12-13	Abbisko Therapeutics Co., Ltd.	Azaarylderivat, herstellungsverfahren dafür und anwendung davon zur verwendung in der pharmazie
CN111662282B (zh) *	2019-03-07	2021-07-06	湖南化工研究院有限公司	氮杂环并吡啶类化合物及其中间体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS552656A (en)	1978-06-22	1980-01-10	Yamanouchi Pharmaceut Co Ltd	Phenyl-substituted nitrogen-containing heterocyclic compound and its preparation
BR9407799A (pt) *	1993-10-12	1997-05-06	Du Pont Merck Pharma	Composição de matéria método de tratamento e composição farmaceutica
US6096753A (en) *	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
CA2268190A1 (en) *	1997-08-06	1999-02-18	Suntory Limited	1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
BR9812944A (pt) *	1997-10-20	2000-08-08	Hoffmann La Roche	Inibidores bicìclicos da cinase
AU7922900A (en) *	1999-10-27	2001-05-08	Novartis Ag	Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
EP1184384A1 (de)	2000-09-01	2002-03-06	Sanofi-Synthelabo	1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
WO2003000682A1 (en)	2001-06-25	2003-01-03	Merck & Co., Inc.	(pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
GB0117506D0 (en)	2001-07-18	2001-09-12	Bayer Ag	Imidazopyridinones
US7109204B2 (en)	2001-08-01	2006-09-19	Merck & Co., Inc.	Tyrosine kinase inhibitors
US20040181066A1 (en)	2001-08-01	2004-09-16	Fraley Mark E.	Tyrosine kinase inhibitors
US6958340B2 (en) *	2001-08-01	2005-10-25	Merck & Co., Inc.	Tyrosine kinase inhibitors
EA007165B1 (ru)	2001-09-21	2006-08-25	Санофи-Авентис	Производные замещенного 2-пиримидинил-6, 7, 8, 9-тетрагидропиримидо [1,2-а]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1, 2-а]пиримидин-5( 1н )она для нейродегенеративных нарушений
CA2457965C (en)	2001-09-21	2010-06-01	Sanofi-Synthelabo	Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
WO2003030909A1 (en)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
GB0129260D0 (en)	2001-12-06	2002-01-23	Eisai London Res Lab Ltd	Pharmaceutical compositions and their uses

2005
- 2005-01-21 WO PCT/US2005/002013 patent/WO2005070932A2/en not_active Ceased
- 2005-01-21 AU AU2005206557A patent/AU2005206557A1/en not_active Abandoned
- 2005-01-21 EP EP05711810A patent/EP1716150B1/de not_active Expired - Lifetime
- 2005-01-21 US US11/041,151 patent/US7504403B2/en not_active Expired - Fee Related
- 2005-01-21 CA CA002553923A patent/CA2553923A1/en not_active Abandoned
- 2005-01-21 JP JP2006551317A patent/JP2007518813A/ja not_active Withdrawn
- 2005-01-21 ES ES05711810T patent/ES2304690T3/es not_active Expired - Lifetime
- 2005-01-21 DE DE602005006240T patent/DE602005006240T2/de not_active Expired - Fee Related
- 2005-01-21 AT AT05711810T patent/ATE393157T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2005070932A3 (en)	2005-10-27
US7504403B2 (en)	2009-03-17
WO2005070932A2 (en)	2005-08-04
EP1716150A2 (de)	2006-11-02
DE602005006240T2 (de)	2009-06-25
JP2007518813A (ja)	2007-07-12
EP1716150B1 (de)	2008-04-23
US20050187223A1 (en)	2005-08-25
AU2005206557A1 (en)	2005-08-04
HK1094890A1 (en)	2007-04-13
DE602005006240D1 (de)	2008-06-05
ES2304690T3 (es)	2008-10-16
CA2553923A1 (en)	2005-08-04

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
WO2003099808A8 (en)	2009-02-05	Substituted heterocyclic compounds and methods of use
WO2008110891A3 (en)	2009-02-19	New heterocyclic compounds
WO2006058064A3 (en)	2006-10-05	Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HRP20050417B1 (hr)	2013-11-08	Antiviralni derivati nukleozida
DE60315336D1 (de)	2007-09-13	Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
WO2006078676A3 (en)	2007-03-29	Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007114827A8 (en)	2009-01-15	Substituted heterocyclic compounds and methods of use
DE60316468D1 (de)	2007-10-31	Pyrimidine verbindungen
NZ597544A (en)	2013-04-26	Modified 4'-nucleosides as antiviral agents
BRPI0517211B8 (pt)	2021-05-25	composto, composição farmacêutica e seu uso.
PE20091458A1 (es)	2009-09-24	Compuestos heterociclicos antiviricos
EP1554280A4 (de)	2006-07-05	Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
WO2007126745A3 (en)	2007-12-21	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
DE60312342D1 (de)	2007-04-19	1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen
MX2009010503A (es)	2009-10-19	Compuestos heterociclicos antiviricos.
EA200900821A1 (ru)	2010-02-26	Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
WO2007136603A3 (en)	2008-01-17	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MY147984A (en)	2013-02-28	Pyrimidine derivatives
JP2012501312A5 (de)	2012-10-11
WO2007083182A3 (en)	2007-11-15	Novel heterocycles
WO2007031829A3 (en)	2007-11-08	Novel pyrimidine carboxamides
ATE393157T1 (de)	2008-05-15	Substituierte heterocyclische verbindungen und anwendungsverfahren
WO2006065590A3 (en)	2006-09-21	Pyridine and pyrimidine antiviral compositions
EA200800975A1 (ru)	2008-08-29	ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
WO2004094379A3 (en)	2005-03-31	3-phenyl-4- (pyrimidin-2-yl) -6- (piperidin-4-yl) derivatives and related compounds as tnf-alpha and il-1 inhibitors for the treatment of inflammations